SGLT-2 inhibitors can prevent hospitalizations for heart failure in all patients regardless of ASCVD (atherosclerotic cardiovascular disease) or heart failure history. They are suitable for all adults with type 2 diabetes unless they are patients with end-stage renal disease or on dialysis.